Company news

GeoVax Labs, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions

October 13, 2025

GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025

October 9, 2025

GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

October 7, 2025

GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit

October 1, 2025

GeoVax Labs Announces $2.5 Million Registered Direct Offering

September 30, 2025

GeoVax Comments on U.S. America First Global Health Strategy and Highlights Company's Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security

September 29, 2025

GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications

September 24, 2025

GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations

September 22, 2025

GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference

September 18, 2025

GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference

September 15, 2025

GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference

September 12, 2025

GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences

September 8, 2025

GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 3, 2025

GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs

August 20, 2025

GeoVax to Present at the Emerging Growth Conference on August 20, 2025

August 18, 2025

GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine

August 7, 2025

GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains

July 30, 2025

GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation

July 29, 2025

GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update

July 28, 2025

GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology

July 28, 2025

GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results

July 24, 2025

GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025

July 22, 2025

GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine

July 21, 2025

GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand

July 16, 2025

GeoVax to Present at the Emerging Growth Conference on July 16, 2025

July 14, 2025

GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat

July 3, 2025

GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives

July 2, 2025

GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering

July 1, 2025

GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection

June 25, 2025

GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy

June 24, 2025

GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting

June 17, 2025

GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA

June 16, 2025

GeoVax to Participate in BIO International Convention 2025

June 12, 2025

GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency

June 11, 2025

GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients

June 10, 2025

GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia

June 9, 2025

GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology

June 4, 2025

GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing

May 29, 2025

GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance

May 27, 2025

GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation

May 21, 2025

GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations

May 20, 2025

GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025

May 8, 2025

GeoVax Expands Gedeptin(R) Patent Portfolio

May 7, 2025

GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production

May 6, 2025

GeoVax Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025

GeoVax Presents Gedeptin(R) Clinical Data at the American Association for Cancer Research Annual Meeting

April 29, 2025

GeoVax Responds to Detection of Clade I Mpox in North Carolina Wastewater

April 24, 2025

GeoVax Highlights Strong Clinical Results Following Presentation of Multi-Antigen COVID-19 Vaccine at the 25th Annual World Vaccine Congress

April 24, 2025

GeoVax to Report First Quarter 2025 Financial Results and Provide Corporate Update on May 1, 2025

April 23, 2025

GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations

April 22, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 6 decks. Every deck is listed under its year.